8-K
false 0001757898 0001757898 2022-07-28 2022-07-28 0001757898 us-gaap:CommonStockMember 2022-07-28 2022-07-28 0001757898 ste:STETwo700SeniorNotesDue2031Member 2022-07-28 2022-07-28 0001757898 ste:Two700SeniorNotesDue2051Member 2022-07-28 2022-07-28

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 28, 2022

 

 

STERIS plc

(Exact Name of Registrant as Specified in Charter)

 

 

 

Ireland   001-38848   98-1455064
(State or Other Jurisdiction
of Incorporation)
 

(Commission

File Number)

  (IRS Employer
Identification No.)

 

70 Sir John Rogerson’s Quay
Dublin 2, Ireland
(Address of Principal Executive Offices)

+353 1 232 2000

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Ordinary Shares. $0.001 par value   STE   New York Stock Exchange
2.700% Senior Notes due 2031   STE/31   New York Stock Exchange
3.750% Senior Notes due 2051   ST/51   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


ITEM 5.07.

Submission of Matters to a Vote of Security Holders.

At STERIS plc’s (the “Company”) 2022 Annual General Meeting of Shareholders (“Meeting”) held on July 28, 2022, shareholders voted on the matters specified below, with the final voting results as specified. According to the certified list of shareholders, there were 100,080,031 Ordinary Shares of the Company outstanding and entitled to vote at the Meeting. There were present at the Meeting, in person or by proxy, the holders of 90,551,193 Ordinary Shares or 90.48% of the outstanding Ordinary Shares of the Company, constituting a quorum.

 

1.

The nominees named below were re-elected to the board of directors of the Company (the “Board of Directors”), each for a one-year term, and the results of the vote were as follows:

 

Nominee

   Votes for      Votes
against
     Abstentions      Broker
non-votes
 

Richard C. Breeden

     81,621,050        5,422,850        390,418        3,116,875  

Daniel A. Carestio

     86,010,378        1,313,188        110,752        3,116,875  

Cynthia L. Feldmann

     81,671,567        5,446,911        315,840        3,116,875  

Christopher S. Holland

     86,303,049        837,836        293,433        3,116,875  

Dr. Jacqueline B. Kosecoff

     50,325,898        36,856,490        251,930        3,116,875  

Paul E. Martin

     85,030,091        2,145,854        258,373        3,116,875  

Dr. Nirav R. Shah

     86,150,710        982,015        301,593        3,116,875  

Dr. Mohsen M. Sohi

     82,629,391        4,550,934        253,993        3,116,875  

Dr. Richard M. Steeves

     86,057,087        1,118,240        258,991        3,116,875  

 

2.

The results of a proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2023 were as follows:

 

Votes for

     82,534,257  

Votes against

     7,884,031  

Abstentions

     132,905  

 

3.

The results of a proposal to appoint Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law to hold office until the conclusion of the Company’s next Annual General Meeting were as follows:

 

Votes for

     82,688,705  

Votes against

     7,727,717  

Abstentions

     134,771  

 

4.

The results of a proposal to authorize the Board of Directors of the Company or the Audit Committee of the Board of Directors to determine the remuneration of Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law were as follows:

 

Votes for

     88,840,271  

Votes against

     1,553,461  

Abstentions

     157,461  

 

5.

The results of a proposal to approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company’s proxy statement dated June 14, 2022, were as follows:

 

Votes for

     83,487,034  

Votes against

     3,718,395  

Abstentions

     228,889  

Broker non-votes

     3,116,875  


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

STERIS plc
By  

/s/ J. Adam Zangerle

  J. Adam Zangerle
  Senior Vice President, General Counsel and Company Secretary

Dated: July 29, 2022

Shareholder Tools